Table 3 Different disease and duration of response
From: Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China
Pathological diagnosis | Target therapy protocol | Patients number (N) | Best responsea | Median (average) DR (months) |
|---|---|---|---|---|
Osteosarcoma | Apatinib alone | 22 | PR | 3.1 (3.7) |
Ewing sarcoma | Apatinib + everolimus & apatinib alone | 10 | PR | 1.5 (3.3) |
Synovial sarcoma | Apatinib alone | 6 | PR | 5.2 (5.8) |
MPNSTc | Apatinib alone | 3 | PR | 8.8 (10.1) |
Epithelioid sarcoma | Apatinib + GTb | 2 | PR | (4.7) |
UPSd | Apatinib alone | 4 | PR | 5.6 (5.0) |
Fibrosarcoma | Apatinib alone | 1 | PR | 2.7 |
Chondrosarcoma | Apatinib alone | 3 | PR | (7.4) |
ASPSe | Apatinib + GTb | 3 | PR | (7.4) |
Extraskeletal osteosarcoma | Apatinib alone | 1 | SD | 6.6 |
Mucinous type liposarcoma | Apatinib alone | 1 | PD | 1.0 |